Bone Biologics Corp — Director's Dealing 2023

Sep 12, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2023-09-11

Reporting Person: Frelick Jeff (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-11	Common Stock	P	9500	$0.6874	Acquired	17204	Direct

Footnotes

F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6898, inclusive. Mr. Frelick undertakes to provide Bone Biologics Corporation, any security holder of Bone Biologics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.